CA2507217C - Compositions and methods for treating neuropathic sensory loss - Google Patents
Compositions and methods for treating neuropathic sensory loss Download PDFInfo
- Publication number
- CA2507217C CA2507217C CA2507217A CA2507217A CA2507217C CA 2507217 C CA2507217 C CA 2507217C CA 2507217 A CA2507217 A CA 2507217A CA 2507217 A CA2507217 A CA 2507217A CA 2507217 C CA2507217 C CA 2507217C
- Authority
- CA
- Canada
- Prior art keywords
- lidocaine
- negative sensory
- sensory phenomena
- neuropathic
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002981 neuropathic effect Effects 0.000 title claims description 31
- 238000000034 method Methods 0.000 title abstract description 11
- 206010040030 Sensory loss Diseases 0.000 title description 15
- 239000000203 mixture Substances 0.000 title description 13
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229960004194 lidocaine Drugs 0.000 claims abstract description 53
- 230000001953 sensory effect Effects 0.000 claims abstract description 49
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 17
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 14
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 13
- 229920000728 polyester Polymers 0.000 claims description 24
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 22
- 239000004744 fabric Substances 0.000 claims description 21
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 20
- 208000004044 Hypesthesia Diseases 0.000 claims description 18
- 239000003589 local anesthetic agent Substances 0.000 claims description 18
- 208000034783 hypoesthesia Diseases 0.000 claims description 15
- 231100000862 numbness Toxicity 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 229960005274 benzocaine Drugs 0.000 claims description 11
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 11
- 229960004919 procaine Drugs 0.000 claims description 11
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 10
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 10
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims description 10
- 229960003150 bupivacaine Drugs 0.000 claims description 10
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960002023 chloroprocaine Drugs 0.000 claims description 10
- 229960003920 cocaine Drugs 0.000 claims description 10
- 229960003976 etidocaine Drugs 0.000 claims description 10
- 229960002409 mepivacaine Drugs 0.000 claims description 10
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 10
- 229960001807 prilocaine Drugs 0.000 claims description 10
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 10
- 229960003981 proparacaine Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 229960002372 tetracaine Drugs 0.000 claims description 10
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 10
- WZQHUXOIBFWXDT-UHFFFAOYSA-N 2-(diethylamino)ethyl 5-(butylamino)-2-hydroxybenzoate;hydrochloride Chemical compound Cl.CCCCNC1=CC=C(O)C(C(=O)OCCN(CC)CC)=C1 WZQHUXOIBFWXDT-UHFFFAOYSA-N 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 9
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 9
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims description 9
- 229960001747 cinchocaine Drugs 0.000 claims description 9
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 9
- -1 polyethylene Polymers 0.000 claims description 9
- 229920000573 polyethylene Polymers 0.000 claims description 9
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 9
- 239000004800 polyvinyl chloride Substances 0.000 claims description 9
- 239000005033 polyvinylidene chloride Substances 0.000 claims description 9
- 229950003255 propoxycaine Drugs 0.000 claims description 9
- 229920003051 synthetic elastomer Polymers 0.000 claims description 9
- 239000005061 synthetic rubber Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 abstract description 13
- 230000003247 decreasing effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 230000009023 proprioceptive sensation Effects 0.000 abstract description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 201000001119 neuropathy Diseases 0.000 description 8
- 230000007823 neuropathy Effects 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003193 general anesthetic agent Substances 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 229940035674 anesthetics Drugs 0.000 description 5
- 229960005015 local anesthetics Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000578 peripheral nerve Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000086254 Arnica montana Species 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010013886 Dysaesthesia Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000001559 benzoic acids Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940066974 medicated patch Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- GTQXPCWVIUCJCK-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-aminobenzoate;oxoborinic acid Chemical compound OB=O.OB=O.OB=O.OB=O.OB=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 GTQXPCWVIUCJCK-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- JJCJKGKSHRXGHT-UHFFFAOYSA-N butanoic acid;2-(diethylamino)ethyl 4-aminobenzoate Chemical compound CCCC(O)=O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 JJCJKGKSHRXGHT-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42920802P | 2002-11-26 | 2002-11-26 | |
| US60/429,208 | 2002-11-26 | ||
| PCT/US2003/037815 WO2004047819A2 (en) | 2002-11-26 | 2003-11-25 | Composition and its use for treating neuropathic sensory loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2507217A1 CA2507217A1 (en) | 2004-06-10 |
| CA2507217C true CA2507217C (en) | 2012-08-28 |
Family
ID=32393523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2507217A Expired - Fee Related CA2507217C (en) | 2002-11-26 | 2003-11-25 | Compositions and methods for treating neuropathic sensory loss |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1565173B1 (enExample) |
| JP (1) | JP2006509766A (enExample) |
| CN (1) | CN1717229A (enExample) |
| AT (1) | ATE420633T1 (enExample) |
| AU (1) | AU2003298710B2 (enExample) |
| CA (1) | CA2507217C (enExample) |
| DE (1) | DE60325885D1 (enExample) |
| ES (1) | ES2319764T3 (enExample) |
| WO (1) | WO2004047819A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
| US7592458B2 (en) | 2006-07-21 | 2009-09-22 | Wright George E | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain |
| CA2732784C (en) * | 2008-08-13 | 2018-09-18 | Neuroquest Inc. | Compositions comprising terpene compounds for treating negative sensory phenomena |
| CA2738524C (en) | 2008-10-02 | 2013-11-26 | Mylan Inc. | Method for making a multilayer adhesive laminate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993018A (ja) * | 1982-11-18 | 1984-05-29 | Sumitomo Chem Co Ltd | 顔面錯感覚症治療薬 |
| US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
-
2003
- 2003-11-25 ES ES03796465T patent/ES2319764T3/es not_active Expired - Lifetime
- 2003-11-25 WO PCT/US2003/037815 patent/WO2004047819A2/en not_active Ceased
- 2003-11-25 JP JP2004555767A patent/JP2006509766A/ja active Pending
- 2003-11-25 CA CA2507217A patent/CA2507217C/en not_active Expired - Fee Related
- 2003-11-25 AU AU2003298710A patent/AU2003298710B2/en not_active Ceased
- 2003-11-25 EP EP03796465A patent/EP1565173B1/en not_active Expired - Lifetime
- 2003-11-25 AT AT03796465T patent/ATE420633T1/de not_active IP Right Cessation
- 2003-11-25 DE DE60325885T patent/DE60325885D1/de not_active Expired - Lifetime
- 2003-11-25 CN CNA2003801041719A patent/CN1717229A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE420633T1 (de) | 2009-01-15 |
| DE60325885D1 (de) | 2009-03-05 |
| CA2507217A1 (en) | 2004-06-10 |
| AU2003298710B2 (en) | 2008-02-07 |
| WO2004047819A2 (en) | 2004-06-10 |
| EP1565173A2 (en) | 2005-08-24 |
| WO2004047819A3 (en) | 2004-07-29 |
| EP1565173B1 (en) | 2009-01-14 |
| ES2319764T3 (es) | 2009-05-12 |
| JP2006509766A (ja) | 2006-03-23 |
| CN1717229A (zh) | 2006-01-04 |
| AU2003298710A1 (en) | 2004-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU777656B2 (en) | Anti-infective compositions for treating disordered tissue such as cold sores | |
| US7687080B2 (en) | Treatment of neuropathy | |
| US5589180A (en) | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine | |
| JP2515902B2 (ja) | ヘルペス後神経痛に関する痛みを軽減するための組成物 | |
| KR950014448B1 (ko) | 소양증 치료를 위한 피부과용 약제 조성물 | |
| EP0506658B1 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| US5667799A (en) | Method for treating headache pain with topical local anesthetic compositions | |
| WO2001047559A9 (fr) | Pastilles a usage externe | |
| PT1833443E (pt) | Preparação refrigerante tópica sob a forma de penso | |
| RU2001111868A (ru) | Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги | |
| WO1996026739A1 (en) | Use of protealytic enzymes in the treatment of insect bites | |
| ES2961655T3 (es) | Medicamento para tratamiento de enfermedad neuropática | |
| AU2003298710B2 (en) | Composition and its use for treating neuropathic sensory loss | |
| US20050112183A1 (en) | Compositions and methods for treating neuropathic sensory loss | |
| US4312865A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
| AU738165B2 (en) | Useful formulations of acid addition salt drugs | |
| Zimmet | Hyaluronidase in the prevention of sclerotherapy‐induced extravasation necrosis: a dose‐response study | |
| WO2002067896A1 (en) | Ibutilide and methanesulfonamide for local anesthetics | |
| US20060127318A1 (en) | Composition and method of a topical treatment of neurodermatitis | |
| Kramer et al. | Overview of Local Anesthesia | |
| AU727736B2 (en) | Method for treating headache pain with topical local anesthetic compositions | |
| JP2006298934A (ja) | 局所的局所麻酔薬組成物を用いる頭痛の痛みを処置するための方法 | |
| CA1142090A (en) | Topical anti-inflammatory composition | |
| JPH0329045B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20191125 |